 Eligible subjects are those with peritoneal carcinomatosis secondary to high-grade appendiceal cancer who have undergone complete cytoreductive surgery CRS and hyperthermic intraperitoneal chemotherapy HIPEC, open or minimally invasive laparoscopic or robotic, who plan to receive 12 months of 5-fluorouracil OR Capecitabine Xeloda, with Bevacizumab Avastin for 12 months, with biochemical and radiologic surveillance. 